Gossamer Bio (GOSS) Expected to Announce Quarterly Earnings on Monday

Key Points

• Gossamer Bio is set to announce its Q2 2025 earnings on August 11th, with analysts predicting a loss of ($0.18) per share and revenues of $4.12 million for the quarter.
• The company recently reported a narrower loss of ($0.16) EPS, exceeding expectations, and had a revenue of $9.89 million, significantly above estimates.
• Several analysts have issued positive ratings for Gossamer Bio, with Goldman Sachs raising its price target from $7.00 to $8.00, reflecting growing confidence in the company's potential.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $4.12 million for the quarter.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $9.89 million for the quarter, compared to the consensus estimate of $3.95 million. Gossamer Bio had a negative return on equity of 128.98% and a negative net margin of 41.12%. On average, analysts expect Gossamer Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Gossamer Bio Stock Up 5.3%

GOSS opened at $2.11 on Monday. The company has a market cap of $478.47 million, a P/E ratio of -9.15 and a beta of 1.95. The business's 50-day moving average price is $1.43 and its 200-day moving average price is $1.21. The company has a current ratio of 5.71, a quick ratio of 5.71 and a debt-to-equity ratio of 6.70. Gossamer Bio has a 12 month low of $0.66 and a 12 month high of $2.18.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Invesco Ltd. purchased a new stake in Gossamer Bio during the 1st quarter valued at about $48,000. Bank of America Corp DE increased its stake in Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock valued at $77,000 after purchasing an additional 43,866 shares during the period. Cubist Systematic Strategies LLC acquired a new position in Gossamer Bio in the first quarter valued at $213,000. Jane Street Group LLC boosted its holdings in shares of Gossamer Bio by 5,250.1% in the first quarter. Jane Street Group LLC now owns 683,423 shares of the company's stock valued at $752,000 after acquiring an additional 670,649 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in Gossamer Bio during the first quarter worth about $770,000. Institutional investors and hedge funds own 81.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Wedbush reaffirmed an "outperform" rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Friday, May 16th. The Goldman Sachs Group increased their price target on Gossamer Bio from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Friday, May 16th. Finally, Scotiabank began coverage on Gossamer Bio in a research report on Monday, July 14th. They issued a "sector outperform" rating and a $11.00 price target for the company.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.